Abstract
The use of voriconazole, a trifluorinated antifungal, has been associated with the development of fluoride excess and periostitis/exostoses. We evaluated a cohort of patients on long-term triazole therapy and found that other fluorinated triazoles (fluconazole and posaconazole) conferred no risk for the development of hyperfluorosis and its complications in our cohort.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adolescent
-
Adult
-
Antifungal Agents / administration & dosage
-
Antifungal Agents / adverse effects*
-
Coccidioides / drug effects
-
Coccidioides / growth & development
-
Coccidioidomycosis / drug therapy*
-
Coccidioidomycosis / microbiology
-
Cohort Studies
-
Exostoses / chemically induced
-
Female
-
Fluconazole / administration & dosage*
-
Fluorides / metabolism
-
Humans
-
Male
-
Microbial Sensitivity Tests
-
Middle Aged
-
Periostitis / chemically induced
-
Pyrimidines / administration & dosage
-
Pyrimidines / adverse effects*
-
Triazoles / administration & dosage*
-
Triazoles / adverse effects*
-
United States
-
Voriconazole
Substances
-
Antifungal Agents
-
Pyrimidines
-
Triazoles
-
posaconazole
-
Fluconazole
-
Voriconazole
-
Fluorides